Background
==========

Effective amelioration of symptoms and induction of remission are goals in treatment of rheumatoid arthritis (RA).

Objectives
==========

Data from a Phase II study for RA treatment with abatacept, a selective co-stimulation modulator, showing induction of remission (DAS-28 score \< 2.6) are presented.

Methods
=======

Patients on background methotrexate (MTX) who met ACR criteria for active RA with ≥ 10 swollen joints (66 joint count) and ≥ 12 tender joints (68 joint count) were randomly assigned to receive 10 mg/kg abatacept (*n*= 115) or placebo (*n*= 119) treatment for 1 year. DAS-28 scores and serum cytokine levels were assessed at days 1, 90, 180 and 360.

Results
=======

Abatacept-treated patients showed a progressive increase in remission rates up to 1 year (analysis not prespecified) compared with placebo (*P*\< 0.001; Fig. [1](#F1){ref-type="fig"}). Abatacept treatment also decreased serum levels of proinflammatory cytokines. In particular, levels of serum IL-6, a multifunctional cytokine that contributes both to acute phase response and to pathological B cell activation, were reduced by 67% at 180 days and by 73% at 360 days (*P*\< 0.05). Placebo-treated patients showed no reduction. Abatacept was generally safe and well tolerated.

![Abatacept increases the remission rate in RA patients refractory to MTX treatment. Means and 95% confidence intervals are shown.](ar1128-1){#F1}

Conclusions
===========

In patients with active RA who were receiving MTX, abatacept treatment significantly improved RA symptoms and produced a progressive increase in remission rates for over one-third of the treatment group, which was sustained at 1 year. In addition, abatacept decreased serum IL-6 levels. The results of this phase II study suggest that abatacept may have potential as therapy for patients with active RA despite MTX treatment.
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